The treatment of liver metastasis from rectal cancer is mainly systemic therapy, which includes chemotherapy combined with vascular targeted drug therapy, immunotherapy and so on. Local treatment can be considered as appropriate when systemic treatment is effective, so the treatment of rectal cancer with liver metastasis is a comprehensive treatment. About 20% to 25% of rectal cancer patients are diagnosed with liver metastasis at the time of initial diagnosis, and about 40% to 50% of patients will have liver metastasis within 3 years after surgery. Overall, the five-year survival rate of patients with stage IV rectal cancer is less than 7%. In the past 20 years, the standard fluorouracil regimen combined with VEGF and EGFR antibody suppressants, as well as the cytotoxic drugs oxaliplatin and irinotecan, can improve the median survival rate to more than 20 months. The commonly used VEGF drug in clinical practice is bevacizumab, and the anti body suppressor of EGFR is cetuximab. In addition, immunotherapy is also under constant exploration. The above is my personal opinion. The specific treatment plan should also be taken under the guidance of professional doctors in professional departments.
